US food and drug regulator approves first injectable drug Apretude for HIV prevention, Financial Times reports, citing a statement from British pharmaceutical company GlaxoSmithKline (GSK). The manufacturer of the drug is ViiV Healthcare, which is majority owned by GSK. Apretude injections need to be injected six times a year, while the current pre-exposure prophylaxis (PREP) regimen provides for daily pills, the newspaper said.. Debra Birnkrant, Director of Antivirals at the FDA's Center for Drug Evaluation and Research, told the Financial Times that the drug will be " It is noted that the retail price of the drug will be $ 3.7 thousand per injection.

ViiV's head of research and development, Kim Smith, added that the company has programs for people without insurance who can't get it.. The company plans to apply for registration of the drug in the UK and EU in 2022. Earlier it was reported that in Japan, scientists have successfully tested an HIV vaccine in macaques. Scientists hope to start human testing of vaccine in five years. Soon after, it became known that American scientists had also successfully tested an RNA vaccine against HIV.. News from in Telegram. Subscribe to our channel https: // t. me / korrespondentnet Author: 1.